Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor

Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult patients in combination with other antiretroviral agents. The recommended dose is a 25 mg tablet once daily taken orally with a meal. Due to cytochrome P450 3A4 enzyme inducti...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2013-02, Vol.68 (2), p.250-256
Main Authors: Sharma, Mamta, Saravolatz, Louis D
Format: Article
Language:English
Subjects:
Anticonvulsants
Antiretroviral drugs
Clinical trials
Drug Interactions
Drug Resistance, Viral
Drug Therapy, Combination - methods
Drug use
HIV
HIV Infections - drug therapy
HIV Infections - virology
HIV-1 - drug effects
Human immunodeficiency virus
Human immunodeficiency virus 1
Humans
Nitriles - adverse effects
Nitriles - pharmacology
Nitriles - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - pharmacology
Pyrimidines - therapeutic use
Reverse Transcriptase Inhibitors - adverse effects
Reverse Transcriptase Inhibitors - pharmacology
Reverse Transcriptase Inhibitors - therapeutic use
Rilpivirine
Treatment Outcome
Virology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult patients in combination with other antiretroviral agents. The recommended dose is a 25 mg tablet once daily taken orally with a meal. Due to cytochrome P450 3A4 enzyme induction or gastric pH increase, rilpivirine cannot be coadministered with a number of other drugs (anticonvulsants, rifabutin, rifampicin, rifapentine, proton pump inhibitors, systemic dexamethasone and St John's wort). Rilpivirine should be used with caution when coadministered with a drug with a known risk for torsade de pointes. Rilpivirine has a better tolerability than a comparative NNRTI, efavirenz, in clinical trials, with fewer central nervous system adverse effects, rashes, lipid abnormalities and discontinuation rates. Virological failure occurs more commonly with higher baseline viral loads (>100,000 copies/mL) and lower baseline CD4 counts (
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dks404